source
- GSK terminates $700 million Alector partnership after recent trial setbacksGSK has decided to end its collaboration with Alector, a biotech focused on neurodegenerative diseases. The agreement originally included a $700 million upfront payment. The move follows two high-…
- Northwest Biotherapeutics' brain cancer therapy faces 931-day delay in UK approvalNorthwest Biotherapeutics, a public biotech developing a brain cancer treatment, filed a marketing application with the UK Medicines and Healthcare products Regulatory Agency (MHRA) in late Decembe…